Syntr Health Technologies, Inc.

Background

Founded in 2016 and headquartered in Irvine, California, Syntr Health Technologies, Inc. specializes in developing medical devices for the processing of autologous adipose tissue at the point of care. The company's mission is to assist physicians with devices that accelerate adipose tissue processing, aiming to reduce recovery times and improve patients' quality of life. Syntr Health Technologies operates within the medical device industry, focusing on aesthetic and reconstructive surgical applications.

Key Strategic Focus

Syntr Health Technologies concentrates on providing innovative solutions for adipose tissue processing, particularly through its flagship product, the SyntrFuge System™. This FDA-cleared device is designed for use in various surgical specialties, including orthopedic, arthroscopic, neurosurgery, gastrointestinal, urological, general, gynecological, thoracic, laparoscopic, and plastic and reconstructive surgeries. The system enables the efficient harvesting, concentrating, and transferring of autologous fat tissue, offering a minimally invasive approach that preserves cell structure and viability. The primary markets targeted include aesthetic body contouring and reconstructive procedures.

Financials and Funding

Syntr Health Technologies has successfully secured funding to support its growth and product development:

• Seed Funding Round (August 2021): The company raised $2.2 million in an oversubscribed seed funding round, with participation from previous investors, angels, and surgeons. The proceeds were allocated to build out sales for the SyntrFuge System and expand the product line.

• Additional Funding (September 2022): An additional $3.19 million was raised in a seed round to further accelerate market penetration of the SyntrFuge System.

Pipeline Development

The SyntrFuge System is the company's primary product, with ongoing efforts to expand its applications:

• Facial Fat Transfer Clinical Study (April 2023): Positive interim results were announced from a multi-center study focusing on the correction of moderate-to-severe mid-face and nasolabial fold volume deficits. The study demonstrated significant improvements in volume retention, skin quality, and patient satisfaction.

• Veterinary Applications (September 2022): A partnership with HAPPYBOND, Inc. was established to combat canine osteoarthritis using the SyntrFugeK9 System, aiming to provide advanced therapy for treating knee and joint osteoarthritis in dogs.

Technological Platform and Innovation

Syntr Health Technologies' innovation is centered around the SyntrFuge System™, a patented device that processes autologous adipose tissue at the point of care. The system concentrates fat tissue while preserving cell structure and viability, which is critical for the tissue to function naturally in the body. This technology offers a minimally invasive approach, processing tissue in minutes and resulting in quick and efficient procedures.

Leadership Team

• Ahmed Zobi: Co-Founder, Chief Executive Officer, and Chairman. Under his leadership, the company achieved FDA clearance for the SyntrFuge System and secured significant funding rounds.

• Hugo Salas: Co-Founder, Chief Operating Officer, Vice President of Business Development, and Board Member. He plays a pivotal role in strategic partnerships and operational management.

• Justin Stovner: Co-Founder and Vice President of Engineering. He leads the engineering team in developing and refining the company's medical devices.

• Dane Shackleford: Board Member and Advisor. Appointed in August 2021, he brings extensive experience from previous roles, including VP of Sales at KCI and VP of Global Sales and Marketing at Spiracur.

Competitor Profile

Market Insights and Dynamics:

The medical device industry, particularly in the realm of adipose tissue processing and aesthetic procedures, is experiencing significant growth. The demand for minimally invasive procedures and autologous tissue applications is driving innovation and competition.

Competitor Analysis:

• Lipogems: A venture capital-backed company based in Milan, Italy, specializing in adipose tissue processing technologies.

• GID BIO: A venture capital-backed company located in Louisville, CO, focusing on regenerative medicine solutions involving adipose tissue.

• Systagenix Wound Management: An early-stage diagnostics business based in West Sussex, United Kingdom, involved in wound care and tissue regeneration.

• Organogenesis Holdings: A corporation headquartered in Canton, MA, specializing in regenerative medicine and tissue engineering.

• 3M: A multinational corporation based in Saint Paul, MN, with a diverse portfolio, including medical devices and supplies.

Strategic Collaborations and Partnerships

In September 2022, Syntr Health Technologies partnered with HAPPYBOND, Inc. to address canine osteoarthritis. This collaboration combines the SyntrFugeK9 System with HAPPYBOND's collagen supplements to provide a synergistic therapy for treating joint osteoarthritis in dogs.

Operational Insights

Syntr Health Technologies differentiates itself through its focus on point-of-care adipose tissue processing, offering minimally invasive solutions that preserve cell viability. The company's strategic initiatives aim to expand its market reach and application of its innovative technologies.